Academisch Ziekenhuis Maastricht
39
7
7
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
12.8%
5 terminated/withdrawn out of 39 trials
72.2%
-14.3% vs industry average
13%
5 trials in Phase 3/4
0%
0 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (39)
Impact of Left-Handed Tailored Endoscopic Mitral Simulation Training on Skill Acquisition for Left-handed Surgeons
Role: lead
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Role: collaborator
Patient Recorded Indexing Measurements
Role: lead
[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin
Role: collaborator
IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study
Role: collaborator
Evaluation of the Use of the FUR to Quantify Tumor Glucose Consumption in Oncologic PET
Role: lead
Perioperative Energy Expenditure in Major Liver Resection
Role: lead
Southeast Netherlands Advanced Metastatic Breast Cancer Registry
Role: lead
Digital Cardiac Counseling Trial: DCC Trial
Role: lead
Detecting Otoconia With CT-Scan
Role: lead
Timely Recovery After Subclinical Heart Failure
Role: lead
Effects of VitamIN K2 and D3 supplementaTion on PET/MRI in Carotid Artery Disease
Role: lead
Chronic Pain Rehabilitation in Patients With Small Fiber Neuropathy
Role: lead
Oral Microbioma and Oral Malignant Disease
Role: lead
Use of "iSuite" During CMR-guided Electrophysiological Procedures
Role: lead
Light Intensity Physical Activity Trial
Role: lead
Pharmacokinetic Boosting of Osimertinib
Role: lead
fMRI-study in Patients With Small Fiber Neuropathy
Role: lead
Clinical Effectiveness of S53P4 Bioactive Glass in Treatment of Long-bone Chronic Osteomyelitis
Role: lead
A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck
Role: collaborator